This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edward J. Zabawski, Jr, DO; Bryan Sands, DO; Dudley Goetz, DO
Dallas Ft Worth Medical Center Grand Prairie, Tex

Mark Naylor, MD
University of Oklahoma Health Sciences Center Oklahoma City

Clay J. Cockerell, MD
University of Texas Southwestern Medical Center Dallas

JAMA. 1997;278(15):1236.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Cidofovir is a nucleotide analog of deoxycytidine monophosphate and has antiviral activity against a broad range of DNA viruses, including cytomegalovirus and herpesviruses.^1-3 Topical cidofovir has been reported as a successful treatment for refractory condyloma acuminatum³ in human immunodeficiency virus infection and recurrent genital herpes.⁴ We report the use of topical cidofovir in 2 patients with verruca vulgaris resistant to repeated conventional therapies.

Report of Cases.

—An 8-year-old girl with no history of significant medical illness had been treated unsuccessfully with numerous conventional therapies (eg, electrodesiccation, topical cantharidin, topical tretinoin, oral cimetidine) for extensive (several hundred lesions), biopsy-proven verruca vulgaris of both lower extremities for 2 years. After obtaining informed consent, we initiated application of 3% topical cidofovir twice daily. Marked erythema and irritation without erosion or ulceration were evident by day 10, and therapy was halted. No systemic adverse effects were noted. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?